[Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic...

Area of Science:

• Urology
• Pharmacology
• Oncology

Context:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men.
• Effective treatment strategies are crucial for managing BPH symptoms and preventing complications.
• 5-alpha reductase inhibitors (5-ARIs) are a key therapeutic class for BPH.

Purpose:

• To compare the efficacy of finasteride-tamsulosin versus dutasteride-tamsulosin in treating BPH over two years.
• To analyze prostate-specific antigen (PSA) variations and therapeutic effects.
• To assess the risk of prostate cancer in patients with PSA < 4 ng/mL during treatment.

Summary:

• A retrospective study of 288 BPH patients (PSA > 4 ng/mL) compared tamsulosin with finasteride versus tamsulosin with dutasteride.
• Both combination therapies significantly reduced PSA and prostate volume. Dutasteride showed faster improvements in IPSS, uroflowmetry, and prostate volume at 3 months.
• PSA reduction greater than 50% correlated with a positive treatment response, reducing the need for surgery. No statistically significant differences in prostate cancer incidence were observed between groups.

Impact:

• Finasteride and dutasteride, when combined with tamsulosin, offer effective BPH management by reducing prostate size and PSA levels.
• The findings support the use of these 5-ARI combinations for BPH, highlighting dutasteride's potentially faster onset of action.
• The study provides evidence that these treatments do not increase prostate cancer risk in the studied patient population.